• USA Home
  • A2846 - A-134974 dihydrochloride hydrate

EMAIL THIS PAGE TO A FRIEND
A2846 Sigma-Aldrich

A-134974 dihydrochloride hydrate

≥98% (HPLC), solid

Synonym: N7-[(1′R,2′S,3′R,4′S)-2′,3′-dihydroxy-4′-aminocyclopentyl]-4-amino-5-iodopyrrolopyrimidine dihydrochloride hydrate

  • Empirical Formula (Hill Notation) C11H14IN5O2 · 2HCl · xH2O

  • Molecular Weight 448.09 (anhydrous basis)

  •  MDL number MFCD08692561

  •  PubChem Substance ID 24890697

  •  NACRES NA.77

Purchase

Properties

Related Categories A to C, A-AM, Abbott, Adenosine Kinase, Adenosine Kinase; ATP:adenosine 5-prime-phosphotransferase (ADK),
Quality Level   100
assay   ≥98% (HPLC)
form   solid
color   off-white to light tan
solubility   H2O: soluble
originator   Abbott
SMILES string   O.Cl.Cl.N[C@H]1C[C@H]([C@H](O)[C@@H]1O)n2cc(I)c3c(N)ncnc23
InChI   1S/C11H14IN5O2.2ClH.H2O/c12-4-2-17(6-1-5(13)8(18)9(6)19)11-7(4)10(14)15-3-16-11;;;/h2-3,5-6,8-9,18-19H,1,13H2,(H2,14,15,16);2*1H;1H2/t5-,6+,8+,9-;;;/m0.../s1
InChI key   INMLNTBMPNIKQK-HWZUHWJPSA-N

Description

Packaging

5 mg in glass bottle

Biochem/physiol Actions

A-134974 is a novel and selective adenosine kinase (AK) inhibitor with IC50 = 60 pM. Systemic A-134974 (i.p.) dose dependently reduced hyperalgesia (ED50= 1 μmol/kg) and at higher doses, reduced locomotor activity (ED50 = 16 μmol/kg). Administration of A-134974 intrathecally (i.t.) was more potent (ED50= 6 nmol) at producing antihyperalgesia than delivering the compound by intracerebralventricular (ED50 = 100 nmol, i.c.v.) or intraplantar (ED50 >300 nmol) routes. In contrast, i.c.v. administration of A-134974 was more effective in reducing locomotor activity than i.t. administration (ED50 values were 1 and >100 nmol, respectively). Increasing the pretreatment time for i.t.-delivered A-134974 caused a greater reduction in locomotor activity (ED50= 10 nmol). This was due to diffusion of A-134974 (i.t.) to supraspinal sites. These data demonstrate that the novel AK inhibitor A-134974 potently reduces thermal hyperalgesia primarily through interactions with spinal sites, whereas its ability to depress locomotor activity is predominantly mediated by supraspinal sites.

Features and Benefits

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold under license from Abbott Laboratories.

Safety & Documentation

Safety Information

Personal Protective Equipment 
RIDADR 
NONH for all modes of transport
WGK Germany 
WGK 3
Flash Point(F) 
Not applicable
Flash Point(C) 
Not applicable

Documents

Certificate of Analysis (COA)

Please Enter a Lot Number
Protocols & Articles

Articles

Adenosine Receptors

Adenosine receptors are members of the superfamily of G protein-coupled receptors and each bears the characteristic motif of seven transmembrane spanning domains. They fall into four known subtypes, ...
Keywords: Atomic absorption spectroscopy, Cancer, Cardiovascular, Diabetes, Diseases, Gene expression, Inflammation, Magnetic resonance spectroscopy, Neurotransmitters, Substitutions, Transduction

Related Products

Technical Service:

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Bulk Ordering & Pricing:

Need larger quantities for your development, manufacturing or research applications?